Abstract For improved intracellular uptake of CpG ODN into macrophages, we developed CpG ODN and mannose conjugate (CpG-Man conjugate) via simple conjugation of a-D-mannose to CpG ODN. CpG-Man conjugate showed greatly enhanced intracellular uptake by 2.1-fold into macrophages, compared to CpG ODN in a TLR-9 receptorspecific manner. In addition, internalized CpG-Man conjugate successfully triggered TNF-a release in macrophages. Taken together, the CpG-Man conjugate can serve as the promising delivery systems of CpG ODN into immune cells as a candidate adjuvant.
Introduction
Macrophages, one of the representative antigen presenting cells, have been well known for its close relation to immune regulation and inflammation (Gordon 2003 ). In particular, the level and types of cytokine induction by macrophages could determine humoral immune responses. Toll-like receptors (TLR) have been highly expressed in macrophages which have an important role for immune responses and cytokine induction. Accordingly, diverse TLR agonists are clinically translated or under clinical trials as a vaccine adjuvant (Krieg 2008) . Oligodeoxynucleotides (ODN) with CpG motifs (CpG ODN) are well-known TLR-9 ligands (Chuang et al. 2014) . Among four classes of CpG ODN, B class of CpG ODN has been popularly investigated for clinical translation (Bode et al. 2011) . After intracellular uptake, CpG ODN binds to TLR-9 receptors and elicit a production of a significant amount of cytokines like TNF-a, IL-6, and IFN-c through the following nuclear factor-jB (NF-jB) pathway (Kim et al. 2015; Klinman 2004) . CpG ODN has been noticed as a promising immune stimulator and vaccine adjuvant.
Due to its physicochemical properties of CpG ODN like hydrodynamic radius and charges, CpG ODN cannot be internalized into cells without carrier systems. Thus, CpG ODNs have been formulated for enhanced intracellular delivery and efficient cytokine induction for macrophages (Kortylewski et al. 2009 ). Diverse carriers such as polymeric micelles and nanoparticles have been developed for the delivery of CpG ODN (Motoyama et al. 2015; Zhang et al. 2016) . The encapsulation of CpG ODN within particles could protect it from nuclease degradation (Asthana et al. 2014) . However, complicated formulation processes and physicochemical stresses during formulation could ruin integrity of CpG ODN. As an alternative approach, nucleotides could be directly conjugated with targeting ligands, which allow enhanced intracellular uptake without cationic carriers (Mok et al. 2010; Nair et al. 2014; Yoo et al. 2014) . A mannose receptor, CD 206, is primarily expressed on macrophages (Mahor et al. 2012; Yu et al. 2013) . Accordingly, the conjugation of mannose (Man) to nanoparticles could provide selective and efficient delivery to macrophages.
In this study, a-D-mannose was simply conjugated to amine functionalized CpG ODN via carbodiimide chemistry for targeted delivery to macrophage cells, RAW264.7. Synthesized CpG ODN and mannose conjugate (CpG-Man Heesun Jung and Gyeonghui Yu contributed equally to this work.
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hjmok@konkuk.ac.kr conjugate) was analyzed by matrix-assisted laser desorption/ionization mass (MADI/MS). The degree of Man conjugation was also measured by fluorescamine assay. After the treatment of tamra-labeled CpG-Man conjugate to RAW264.7, the intracellular uptake level of the CpGMan conjugate was determined by the quantification of fluorescence intensities. In addition, the amount of induced TNF-a by CpG-Man conjugate for RAW264.7 was measured by enzyme-linked immunosorbent assay (ELISA).
Materials and methods

Materials
Amine and fluorescent tamra modified CpG ODN 1826 (5 0 -TCCATGACGTTCCTGACGTT-3 0 ) at the 3 0 -end and the 5 0 -end were obtained from Bioneer Inc. (Daejeon, Korea). a-D-mannopyranosylphenyl isothiocyanate (Man) was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). D-mannosamine hydrochloride and fluorescamine were obtained from Sigma Aldrich (St. Louis, MO, USA). Dulbecco's modified Eagle's medium, penicillin/streptomycin (P/S), and fetal bovine serum were purchased from Gibco BRL (Grand Island, NY, USA). Desalting column (MWCO 7 kDa) was purchased from thermo scientific (Rock-ford, IL, USA). A mouse TNF-a ELISA kit was obtained from BD Biosciences (Franklin, Lake, NJ).
Preparation of CpG-Man conjugate
To synthesize CpG-Man conjugate, 3 0 -amine modified CpG ODN 1826 (200 lg, 32 nmol) in sodium bicarbonate solution (pH 9.0) was reacted with a-D-mannopyranosylphenyl isothiocyanate (100 lg, 320 nmol) overnight. For removing excessive and unreacted a-D-mannose, the reactant was purified via a desalting column (MWCO 7 kDa) according to manufacturer's protocol.
Characterization of CpG-Man
The amount of amine groups was measured by fluorescamine assay according to previous study . Synthesized CpG-Man conjugate (150 lg) was mixed with fluorescamine reagent in acetone (2 mg/ml) at a sample/fluorescamine volume ratio of 10 and incubated for 10 min. Fluorescence intensities of the solutions were measured by fluorospectrophotometer (Gemini EM microplate reader, Molecular Device, CA, USA) at an excitation and emission wavelength of 390 and 475 nm, respectively. The amount of amine groups in reactant was calculated using standard plot of amine-modified CpG ODN.
For MALDI/MS analysis, the dried CpG-Man sample was mixed with 2 0 ,4 0 ,6 0 -trihydroxyacetophenone (THAP) in 70 % acetonitrile (ACN)/0.1 % trifluoroacetic acid (TFA) as the matrix. Samples were analyzed using MADI/ MS (Ultraflextreme, Bruker, Germany) with a smartbeam-II TM laser as the ionization source. All the spectra were required using an ion source voltage of 25 kV and 1 kHz repetition rate in the positive mode with an average of 5000 shots.
Intracellular uptake of CpG-Man conjugate
For intracellular uptake, both 5 0 -tamra-and 3 0 -aminemodified CpG ODN were conjugated to Man under the dark condition, named by tamra-modified CpG-Man, as described above. RAW264.7 cells were seeded in 24-well plate at a density of 8 9 10 4 cells/well. After 24-h incubation, the cells were treated with the tamra-modified CpG-Man at a concentration of 1.6 lM in serum-containing medium. As a control, both 5 0 -tamra-and 3 0 -aminemodified CpG ODN were also treated to cells at same concentration. After incubation for 24 h, the cells were washed with phosphate buffer saline (PBS) twice, and then treated with detergent as lysis buffer. The lysed cells were gathered in tube, and spun down at 13,000 rpm, 4°C for 10 min. The supernatant was measured by IVIS imaging system (LuminaII; Caliper Life Sciences, USA) at an excitation and emission wavelength of 535 and 570 nm, respectively.
For the competition assay, RAW264.7 cells were seeded in 24-well plate at a density of 8 9 10 4 cells/well. After 24-h incubation, the cells were pre-incubated with the Dmannosamine at a concentration of 0.5, 5.0, and 50 mM (Kim et al. 2016) . After 1-h incubation, tamra modified CpG-Man and 5 0 -tamra CpG ODN at a concentration of 1.6 lM in serum-containing medium. After incubation for 24 h, cells were washed with PBS twice, and then treated with detergent as lysis buffer. The lysed cells were gathered in tube, and centrifuged at 13,000 rpm, 4°C for 10 min. The supernatant was measured by IVIS imaging system at an excitation and emission wavelength of 535 and 570 nm.
In vitro cytokine release study RAW264.7 cells were seeded in 24-well plates at a density of 8 9 10 4 cells/well 24 h prior to transfection. The cells were treated with CpG ODN and CpG-Man conjugate at a final concentration of 0.5, 2.5, and 5.0 lM in serum-free medium for 8 h. After replacing the incubation solution with serum-containing medium, cells were incubated 16 h.
The supernatant of the cells was gained and centrifuged at 13,000 rpm, 10 min, 4°C and the amount of TNF-a protein in the supernatant was measured by a mouse TNF-a ELISA kit.
Results and discussion
Synthesis of CpG-Man conjugate
Synthetic schemes for the preparation of CpG-Man conjugates are shown in Fig. 1(A) . Amine groups at the 3 0 -end of CpG ODN in sodium bicarbonate buffer (pH 9.0) were reacted with isothiocyanate group of a-D-mannopyranosylphenyl isothiocyanate at room temperature. After reaction, a-D-mannose was covalently conjugated to the 3 0 -end of CpG ODN via isourea bonds. After reaction, unreacted CpG ODN and a-D-mannose were eliminated by purification using desalting column (MWCO 7 kDa). As shown in Fig. 1(B) , a-D-mannose was adopted as a targeting ligand for facile interactions of CpG with macrophages. As well known, mannose receptor, CD 206 (cluster of differentiation), is highly expressed in macrophages. Accordingly, interactions between a-D-mannose ligands and mannose receptors have been popularly used for targeted delivery of nanoparticles (Motoyama et al. 2015; Yu et al. 2013 ). In the cells, CD 206 recognizes saccharide chains including a-D-mannose or fucose and enhances their endocytosis (East and Isacke 2002) . As shown in Fig. 1(B) , once the CpG-Man conjugate is internalized into cells, CpG-Man conjugate is interacted with TLR-9, which triggers NK-jB signaling pathway. As a consequence of these signaling cascades, TNF-a and pro-inflammatory response is induced.
Characterization of CpG-Man conjugates
The amount of a-D-mannose modification was calculated by fluorescamine assay, as shown in Fig. 2(A) . After conjugation reaction, the amount of primary amine groups in solution was significantly reduced down to 2.7 ± 0.8 %. This result indicates that more than 95 % of primary amine groups in CpG ODN were modified with a-D-mannose. To confirm the conjugation, CpG-Man conjugate was analyzed by MALDI/MS. As shown in Fig. 2(B) , the CpGMan conjugate was shown at a maximum peak *6470 Da, while CpG ODN exhibits at *6150 Da. The difference of about 320 Da before and after the a-D-mannose conjugation was almost matched with the molecular weight of conjugated a-D-mannose (313.3 Da).
Intracellular uptake of CpG-Man conjugate
To determine whether a-D-mannose in CpG-Man conjugate could facilitate its internalization into macrophages, fluorescent-labeled CpG ODN (5 0 -tamra conjugated CpG) was conjugated with a-D-mannose and treated to RAW264.7 cells for 24 h. It should be also noted that complicated intracellular routes like endosome escape are not needed for CpG ODN delivery systems because TLR-9 binds to CpGMan conjugate in phagolysosomes. Thus, only CpG-Man conjugate was treated to cells without additive reagent. As shown in Fig. 3(A) , total flux of cells treated with tamramodified CpG-NH 2 and tamra-modified CpG-Man conjugate were 10.5 ± 2.3 and 21.7 ± 6.8, respectively. Approximately, 2.1-fold higher uptake was shown by tamramodified CpG-Man, compared to CpG-NH 2 as a control. According to the previous study, a-D-mannose conjugation onto nanoparticles increased intracellular uptake by threefold (Yu et al. 2013) . This difference in the extent of cellular uptake might be attributed to the density of a-Dmannose in biomaterials.
To verify internalization of CpG-Man conjugate into RAW264.7 cells is mediated by mannose receptor, CD206, in a mannose-specific manner, competitive uptake experiment was performed using D-mannosamine in RAW264.7 cells. After pre-incubation with D-mannosamine, cells were treated with CpG-Man conjugates for 1 h. As shown in Fig. 3(B) , the amount of internalized CpG-Man conjugate was gradually decreased by addition of D-mannosamine. When D-mannosamine was treated at a concentration of 0.5, 5.0, and 50 mM, the total flux decreased to 35.9 ± 2.8, 35.1 ± 0.8, and 15.8 ± 8.3 % of control, respectively. However, no significant decrease in uptake was shown for cells treated with CpG-NH 2 . This result clearly indicates that CpG-Man conjugate was internalized into the RAW264.7 cells by mannose receptor-mediated endocytosis.
Induction of TNF-a by CpG-Man conjugate
To determine the extent of cytokine induction by CpG ODN, the level of TNF-a was quantitatively measured after treatment with CpG-NH 2 and CpG-Man conjugate for RAW264.7 cells at a concentration of 0.5, 2.5, and 5.0 lM. As shown in Fig. 4 , the amount of TNF-a was increased in a concentration dependent manner by both CpG ODN and CpG-Man conjugate. As shown in Fig. 4 , CpG ODN triggered TNF-a release of 104.8 ± 13.4, 221.2 ± 7.3, and 420.4 ± 59.6 pg/ml after treatment at the CpG concentration of 0.5, 2.5, and 5.0 lM, respectively. The amount of TNF-a by the treatment with CpG-Man conjugate at the CpG concentrations of 0.5, 2.5, and 5.0 lM were 268.2 ± 81.5, 385.6 ± 19.1, and 613.5 ± 53.1 pg/ml, respectively. Released TNF-a levels by CpG-Man conjugate were 2.6, 1.7, and 1.5-fold higher than that of CpG ODN at each concentration. This result suggests that CpGMan conjugate could be internalized into the RAW264.7 cells much more efficiently than CpG ODN probably due to facile interaction with TLR-9 receptors.
In this study, we demonstrated simply conjugation of a-D-mannose conjugation to CpG ODN could provide enhanced intracellular uptake into macrophages and following cytokine induction. CpG-Man conjugate showed 2.1-fold higher intracellular uptake into macrophages, compared to CpG ODN in a TLR-9 receptor-specific manner. In addition, internalized CpG-Man conjugate successfully triggered TNF-a release in macrophages. Taken together, the CpG-Man conjugate can serve as promising candidate delivery systems of CpG ODN into immune cells as an immune stimulating molecule.
